Ambu A/S (AMBUb)

228.20
-3.60(-1.55%)
  • Volume:
    716,760
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    224.90 - 230.90

AMBUb Overview

Prev. Close
231.8
Day's Range
224.9-230.9
Revenue
3.83B
Open
229.2
52 wk Range
159.9-358.7
EPS
1.12
Volume
716,760
Market Cap
57.88B
Dividend (Yield)
0.29
(0.13%)
Average Vol. (3m)
810,175
P/E Ratio
203.39
Beta
1.17
1-Year Change
2.1%
Shares Outstanding
253,643,109
Next Earnings Date
Aug 17, 2021
What is your sentiment on Ambu A/S?
or
Market is currently closed. Voting is open during market hours.

Ambu A/S News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellBuy
Technical IndicatorsNeutralStrong BuySellStrong SellBuy
SummaryNeutralNeutralSellStrong SellBuy

Ambu A/S Company Profile

Ambu A/S Company Profile

Employees
4290
Market
Denmark

Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products from resuscitators, face masks and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.

Read More
  • Ambu (AMBU B) initiated with a Buy at Berenberg, Berenberg analyst Michael Healy initiated coverage of Ambu with a Buy rating and DKK 291 price target. Ambu is a leader in the "nascent" single-use endoscopy market, one of the fastest-growing segments in medical technology.
    0
    • Sack them all. Big talking American with their grand ideas of Sales at all cost.. . . Down here in Australia, every single American CEO they have tried in the past 20 years have run their companies to the ground and smashed the culture.. . . A great shame I have a very large position in this otherwise great company
      1
      • Feels like the Board of Directors do not like us shareholders. Time to spill the Board. Literally billions in value has been destroyed.
        0
        • They should not have cut Lars.
          0
        • René Rasmussen  Yep, gargantuan mistake. If you read the story of the Chairman, you will see he was fired as CEO from ALK in 2016. Was this revenge because he feels he was treated poorly? Either way I will post on their Facebook soon as I did here. It has cost me a lot of money.
          0
      • Remember when Lundbeck lost their CEO two years ago.. Same reaction and then soon forgotten.
        1
        • Ucchhh what fall today, and I just buy up in the fall. Hope it Will repair next week.
          0
          • Ambu is still a strong case. But it will take some month to stabelice.
            0
          • The leadership of ambu handles it without care.
            0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.